Search Results
Oct 20, 2025, 02:49 ET JSBC Unveils "Chinese Wisdom" Book Series for Global Audiences
storytelling, the book series is meant to serve as a gateway to understanding China's contributions to global thought. Upcoming titles include When Socrates Met Confucius and Architectural China Season 1, further enriching the collection. Available worldwide, the books cater
More news about: JSBC
Oct 20, 2025, 02:44 ET ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
The results showed that the RC48-C016 study met the dual primary endpoints of Progression-Free Survival (PFS) and Overall Survival (OS). The Blinded Independent Central Review (BICR)-assessed median
More news about: RemeGen Co., Ltd
Oct 19, 2025, 19:30 ET IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
of vision in these patients. About the GATHER Clinical Trials IZERVAY met its primary endpoint in the GATHER1 (
More news about: Astellas Pharma Inc.
Oct 19, 2025, 11:37 ET HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
Symposium, and the results of the HARMONi-6 clinical trial were simultaneously published in The Lancet. The HARMONi-6 study met its primary endpoint of progression-free survival (PFS), demonstrating a decisive and strong positive outcome with both statistically significant and
More news about: Akeso, Inc.
Oct 19, 2025, 10:30 ET Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
(EGFR) and MET, two key tumor drivers, are overexpressed in 80 to 90 percent of HNSCC tumors, highlighting their role as potential treatment targets.7,8,9 RYBREVANT®, the world's first bispecific antibody approved for lung cancer, inhibits EGFR and MET, in addition to
More news about: Johnson & Johnson
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced positive topline results from the BL-B01D1-301 trial. The trial has met one of the dual primary endpoints (BICR-assessed ORR) as iza-bren has demonstrated a statistically significant and clinically meaningful improvement
More news about: SystImmune, Inc.
Oct 19, 2025, 02:00 ET Wialon annonce le Top 10 des fabricants de matériel GPS pour 2025
plus de 900 000 appareils connectés sur la plateforme Wialon. Le classement Wialon Top 10, publié chaque année, met en avant les fabricants dont les appareils ont été le plus souvent connectés à Wialon au cours des 12 derniers mois.
More news about: Wialon
Oct 18, 2025, 16:46 ET One Heung Kong a publié, en collaboration avec d'autres institutions, le Livre blanc sur les environnements de vie durables et sains à l'échelle mondiale
confort microclimatique, assurant une couverture complète des espaces extérieurs et intérieurs. En s'appuyant sur une expertise pluridisciplinaire, il met en évidence les paramètres fondamentaux et les principes de conception d'un environnement de vie sain. Selon Mei Hing Chak, présidente
More news about: Heungkong Group
Oct 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Hain Celestial Group, Inc. - HAIN
taking decisive action to optimize cash, deleverage our balance sheet, stabilize sales, and improve profitability as we recognize our performance has not met expectations[.]" On this news, Hain's stock price fell $0.53 per share, or 24.65%, to close at $1.62 per share on September
More news about: Pomerantz LLP
Oct 18, 2025, 03:00 ET Florida Cancer Specialists & Research Institute Shaping the Future of Cancer Care at Global Congress
of a first-in human study: A tumor-associated Mucin 1 (TA-MUC1)–directed Antibody–drug Conjugate (ADC), in Patients (pts) with Advanced/Metastatic (adv/met) Solid Tumors. The following physician leaders are first authors of poster presentations at the ESMO
More news about: Florida Cancer Specialists & Research Institute
Oct 17, 2025, 18:38 ET Huawei Digital Power helpt ASEAN om koolstofvrije transformatie te bereiken met netwerkvormende technologieën voor alle scenario's
grensoverschrijdende overdracht van hernieuwbare energie essentieel zijn om koolstofneutraliteit te bereiken. Met name de stabiele transmissie en consumptie van elektriciteit voor elektriciteitsnetten met een groot aandeel hernieuwbare energie zijn van cruciaal belang. In een tijdspanne van meer dan tien jaar
More news about: Huawei
Oct 17, 2025, 17:00 ET Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals
More news about: Citius Pharmaceuticals, Inc.
Oct 17, 2025, 15:50 ET Huawei onthult geüpgradede AI WAN-oplossing met AI-gerichte architectuur om de groei van carriers te stimuleren
UBBF 2025 in Parijs op 14 oktober werd de Net5.5G Intelligent IP Network Summit gehouden, met als thema "Thrive with Net5.5G for All Intelligence". Huawei introduceerde haar volledig geüpgradede AI WAN-oplossing met een AI-gerichte architectuur. Door alertheid voor ervaringen, limieten voor computernetwerken,
More news about: Huawei
Oct 17, 2025, 14:02 ET The Inner Circle acknowledges, Anna S Rickell as a Pinnacle Professional Member Inner Circle of Excellence
Presbyterian Church. These groups, which she has led for over 13 years, support individuals coping with loss. She also leads a second group that has met regularly for six years. Anna remains actively licensed in South Carolina and continues her work with great pride. She is a founding member of the Board-Certified
More news about: The Inner Circle
Oct 17, 2025, 10:29 ET H.I.G. WhiteHorse verstrekt financiering aan Summit Group
WhiteHorse, het kredietfiliaal van H.I.G. Capital ("H.I.G."), een toonaangevende wereldwijde alternatieve beleggingsonderneming met $ 70 miljard aan kapitaal onder beheer, kondigt met genoegen aan dat het £ 81 miljoen aan eersteklas, senior gedekte kredietfaciliteiten heeft verstrekt aan Summit Group ("Summit"),
More news about: H.I.G. Capital
Oct 17, 2025, 10:00 ET Toyota Motor North America Takes Top Honors as Grand Winner of 2025 ARF David Ogilvy Awards
Airlines – "That's a Big Flex" (GSD&M) Hellmann's / Unilever – "When Sally Met Hellmann's" (VML) Verizon – "We Get It. Life Happens." (Ogilvy)
More news about: The Advertising Research Foundation
Oct 17, 2025, 09:37 ET A.D.A.M. Innovations en SOPHiA GENETICS werken samen om vloeibare biopsietests en begeleidende diagnostiek voor precisieloncologie te bevorderen in Japan
brengen via het SOPHiA DDM™ platform met AI om gepersonaliseerd kankeronderzoek in het hele land te bevorderen. De samenwerking zal zich in eerste instantie richten op de lancering van de vloeibare biopsietoepassing MSK-ACCESS®, die werkt met SOPHiA DDMTM. Deze innovatieve
More news about: SOPHiA GENETICS
Oct 17, 2025, 08:36 ET Re-imagining Neo-Pragmatic Lifestyle: EPWK Launches Strategic Upgrade with "EPWK Curated Goods"
experience filled with surprise and aesthetic delight. In an era of highly developed material supply, consumers' basic needs are fully met. The prevailing dilemma is no longer "can I buy it?" but rather the decision-making struggle of "what is truly worthwhile?" Concurrently, a consumption
More news about: EPWK HOLDINGS LTD.
Oct 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
similar therapeutic benefits. From Week 8 through Week 48, more than half of all participants across both treatment groups met the response threshold for CGI-TD and PGIC, with 90% (18/20) of participants on continuous INGREZZA 40 mg treatment being "much improved" or "very much
More news about: Neurocrine Biosciences, Inc.
Oct 17, 2025, 08:00 ET Apnimed To Present Additional Phase 3 Data for AD109, an Investigational Oral Pill for Obstructive Sleep Apnea, at CHEST 2025 Annual Meeting
The additional data built on previously reported topline results show that both studies met their primary endpoint, reduction in apnea-hypopnea index (AHI) at 26 weeks, and across both studies, AD109 demonstrated clinically meaningful improvements
More news about: Apnimed, Inc.
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
positive nodes or 1-3 positive nodes and at least one of the following: tumors that were ≥5 cm or Grade 3. Patients enrolled in Cohort 2 could not have met the eligibility criteria for Cohort 1. To be enrolled in Cohort 2 (n=517), patients had to have 1-3 positive nodes and Ki-67 score ≥20%. Patients in
More news about: Eli Lilly and Company
Oct 17, 2025, 03:02 ET Proya Cosmetics dévoile sa vision de la beauté de demain au salon Cosmetic 360, entre avancées scientifiques et innovations de marques
Cette année, Proya Cosmetics met en avant ses technologies d'intelligence artificielle déployées sur l'ensemble de sa chaîne de valeur : analyse des comportements consommateurs, recherche
More news about: Proya Cosmetics
Oct 17, 2025, 00:15 ET Education Cannot Wait Provides Additional US$2 Million to Sudanese Refugees in Chad
total resources, including US$69.6 million for the education response. Prior to ECW's latest investment, only 22% of this funding requirement had been met. To scale-up its response to the Sudan regional refugee crisis, ECW is calling on donors and the private sector to urgently mobilize
More news about: Education Cannot Wait
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
Wang Qunbin. It is worth noting that on 9 October, the Phase III clinical trial of HANSIZHUANG for perioperative gastric cancer met its primary endpoint, supporting an early drug application for market approval. This achievement suggests that gastric cancer patients may no longer
More news about: Fosun
Oct 16, 2025, 20:00 ET ORVANA REPORTS Q4 FY2025 PRODUCTION AND EXPLORATION RESULTS FROM OROVALLE, SPAIN
stockpiled and is scheduled for milling in fiscal 2026. Copper production of 3.6 million pounds during the fiscal year 2025 met the 2025 production guidance of 3,500 to 3,700 K lbs.
More news about: Orvana Minerals Corp.